Last updated: October 31, 2026
Cardizem is the former U.S. brand for diltiazem, a calcium-channel blocker used primarily for hypertension, chronic stable angina, vasospastic angina, and certain supraventricular tachyarrhythmias. Its commercial trajectory is now driven by low-cost generic diltiazem rather than branded sales.
The principal conclusions are:
- Cardizem has lost meaningful U.S. market exclusivity.
- Generic competition covers immediate-release tablets, extended-release capsules, extended-release tablets, and injectable diltiazem.
- No current Cardizem-branded product appears to have a commercially significant exclusivity position in the United States.
- Public companies generally do not disclose diltiazem revenue as a separate product line.
- Financial value resides in generic manufacturing scale, hospital contracts, supply reliability, and formulation know-how rather than in the Cardizem trademark.
- Patent litigation surrounding Cardizem CD is historical. It does not create a current U.S. entry barrier comparable to a protected branded product.
What is Cardizem and which formulations are marketed?
Cardizem is a brand associated with diltiazem hydrochloride. Diltiazem is a nondihydropyridine calcium-channel blocker that reduces cardiac conduction and myocardial oxygen demand. FDA-approved uses vary by formulation and label.
| Cardizem formulation |
Delivery profile |
Principal historical use |
Current commercial position |
| Cardizem tablets |
Immediate release |
Hypertension and angina |
Genericized |
| Cardizem CD capsules |
Once-daily extended release |
Hypertension and angina |
Genericized |
| Cardizem LA tablets |
Once-daily extended release |
Hypertension and angina |
Genericized |
| Injectable diltiazem |
Immediate intravenous delivery |
Atrial fibrillation, atrial flutter, and rate control |
Hospital generic market |
| Generic extended-release capsules and tablets |
Modified release |
Hypertension and angina |
Multiple suppliers |
FDA labeling states that diltiazem products differ in release mechanism, dosing frequency, and clinical use. Extended-release products are not automatically interchangeable across formulations because release technology and labeled dosing schedules differ.[1-3]
Cardizem should therefore be analyzed as a portfolio of dosage forms rather than as a single product.
When did Cardizem lose exclusivity?
Cardizem lost practical market exclusivity after generic diltiazem products entered the U.S. market. Immediate-release diltiazem has been generic for decades, while extended-release products were exposed to abbreviated new drug applications after the relevant formulation patents and regulatory protections ceased to block entry.
The original branded franchise is now mature. FDA’s Orange Book and Drugs@FDA records contain historical Cardizem approvals and patent listings, but the commercial relevance of those listings is limited because generic products are widely available.[4]
| Exclusivity category |
Current assessment |
| New chemical entity exclusivity |
Expired |
| Original Cardizem formulation protection |
Expired or commercially ineffective |
| Current branded regulatory exclusivity |
No material position identified |
| Generic approval pathway |
ANDA-based competition |
| Hospital injectable market |
Generic competition with supplier concentration risk |
| Biosimilar pathway |
Not applicable |
Diltiazem is a small-molecule drug. Biosimilar competition does not apply. Competition occurs through ANDAs, not applications under the biologics licensing framework.
What patents protect Cardizem and diltiazem products?
The principal historical patent dispute involved Cardizem CD and U.S. Patent No. 5,529,791, a formulation-related patent associated with Hoechst Marion Roussel and its successors. The patent was litigated against generic entrants, including Andrx Corporation. It no longer provides a current blocking right against U.S. generic entry.
Historical patent and litigation profile
| Patent or legal asset |
Subject matter |
Historical relevance |
Current impact |
| U.S. Patent No. 5,529,791 |
Cardizem CD extended-release formulation technology |
Central to generic-entry litigation |
Expired; no current blocking effect |
| Cardizem trademark |
Brand identity |
Supported historical premium pricing |
Limited value after generic substitution |
| Product labeling |
Approved indications and dosing |
Supports regulatory compliance |
Does not prevent generic entry |
| Manufacturing know-how |
Release profile and dosage-form production |
Can affect product quality and supply |
May remain commercially relevant |
The value of residual intellectual property is concentrated in manufacturing process control, dissolution performance, stability, and regulatory know-how. Those assets can support a generic supplier but generally do not create a durable monopoly.
What patent litigation affected Cardizem?
Cardizem CD generated significant U.S. pharmaceutical antitrust litigation. Andrx filed an ANDA for a generic extended-release diltiazem product and became involved in patent litigation with Hoechst Marion Roussel. The dispute later produced litigation concerning the commercial effects of agreements that delayed generic entry.
The U.S. Supreme Court addressed the broader antitrust implications of pharmaceutical reverse-payment arrangements in Federal Trade Commission v. Actavis, Inc. The case did not decide Cardizem directly, but Cardizem-related litigation became part of the regulatory and commercial history surrounding generic-delay agreements.[5]
The key business effects were:
- Delayed generic competition during the protected period.
- Preservation of branded Cardizem CD pricing for longer than would have occurred under immediate generic entry.
- Subsequent antitrust exposure for payment arrangements that restricted generic launch.
- Increased scrutiny of settlements between branded manufacturers and ANDA filers.
No current Cardizem litigation is known to restore branded exclusivity or materially restrict the mature generic market.
What is the Orange Book status of Cardizem?
The Orange Book remains the primary FDA source for approved drug products, therapeutic equivalence evaluations, and listed patents. Cardizem historical products and their generic equivalents are reflected through FDA approval records and therapeutic-equivalence data.[4]
The commercial interpretation is straightforward:
- Historical patents may remain visible in archival records.
- Visibility in the Orange Book does not mean that a patent remains enforceable.
- Expired patents do not prevent ANDA approval or generic launch.
- The relevant current question is whether an unexpired, enforceable patent is listed against an active reference product and creates a valid basis for a Paragraph IV dispute.
For Cardizem, the mature generic market indicates that no active Orange Book listing has preserved a commercially meaningful branded barrier.
Which companies compete in the diltiazem market?
Diltiazem competition is fragmented across branded remnants, generic oral products, and injectable hospital products. Suppliers have included large generic manufacturers and specialty pharmaceutical companies with cardiovascular portfolios.
Common competitive categories include:
Oral generic manufacturers
Generic diltiazem products have been supplied by companies such as:
- Teva Pharmaceuticals
- Mylan, now part of Viatris
- Dr. Reddy’s Laboratories
- Zydus Pharmaceuticals
- Sun Pharmaceutical Industries
- Lupin
- Rising Pharmaceuticals
- Epic Pharma
- Amneal and other U.S. generic suppliers
Supplier participation varies by strength, dosage form, market period, and FDA approval status. A manufacturer may supply immediate-release tablets without supplying the same extended-release capsule or tablet product.
Hospital injectable suppliers
The injectable market is influenced by hospital purchasing contracts, wholesaler concentration, manufacturing capacity, and shortages. Suppliers may include Hikma Pharmaceuticals, Pfizer subsidiaries, Fresenius Kabi, and other approved manufacturers depending on the product and period.
Injectable diltiazem has a different economic profile from oral diltiazem. Hospitals value dependable supply, vial availability, contract pricing, and shortage resilience more than brand recognition.
How strong is the Cardizem patent estate?
The current Cardizem patent estate is weak as a market-exclusion asset.
| Patent-estate factor |
Assessment |
| Composition-of-matter protection |
Expired |
| Core formulation patents |
Historical and expired |
| Method-of-use patents |
No current barrier of material commercial significance identified |
| Orange Book leverage |
Limited |
| Generic substitution risk |
High |
| Manufacturing complexity |
Moderate for modified-release products |
| Litigation risk |
Low relative to active specialty drugs |
| Geographic protection |
Primarily historical U.S. protection; no global monopoly |
Modified-release diltiazem products can require formulation development, dissolution testing, stability work, and FDA bioequivalence support. Those requirements create execution risk but do not amount to patent exclusivity.
What generic-entry risks exist for Cardizem?
Generic-entry risk is no longer an event risk for Cardizem. It is the established market structure.
The more relevant risks are:
- Price erosion from additional ANDA approvals.
- Contract loss to lower-cost suppliers.
- Supply interruption caused by manufacturing or regulatory problems.
- Product-specific shortages, especially for injectable presentations.
- Pharmacy substitution away from the Cardizem brand.
- Low margins for low-volume strengths.
- Regulatory action involving manufacturing quality or bioequivalence.
- Formulation-specific competition where only a limited number of suppliers remain.
Extended-release products can retain somewhat better pricing than simple immediate-release tablets because fewer manufacturers may compete in a particular strength or release technology. That pricing advantage is usually fragile and can disappear after a new ANDA launch.
What is the financial trajectory for Cardizem?
Cardizem’s financial trajectory is a transition from branded cardiovascular revenue to mature generic economics.
Historical phase
Cardizem generated branded revenue when the manufacturer controlled the product’s formulation, physician recognition, and distribution. Extended-release Cardizem CD supported higher pricing than immediate-release diltiazem because once-daily dosing provided commercial differentiation.
Generic-entry phase
Generic entry reduced:
- Average selling prices
- Branded prescription volume
- Pharmacy retention of the Cardizem brand
- Manufacturer control over channel economics
- Long-term value of the trademark
The magnitude and timing of erosion depended on the dosage form and number of generic entrants.
Mature phase
In the mature market, revenue is determined by:
- Volume of prescriptions and hospital use
- Number of approved suppliers
- Wholesale acquisition price
- Contract rebates
- Manufacturing cost
- API sourcing
- Product shortages
- Strength-specific demand
Public company filings do not generally report Cardizem revenue separately. As a result, a reliable standalone Cardizem revenue series is not available from issuer disclosures. The economic value is embedded in broader cardiovascular, generic, or hospital-product segments.
| Financial driver |
Expected effect |
| Additional oral generic entrants |
Lower price and share per supplier |
| Limited supplier count |
Potential temporary price stability |
| Hospital injectable demand |
Supports recurring volume |
| Product shortage |
Can increase short-term revenue but raises supply obligations |
| Cardizem brand recognition |
Limited ability to sustain premium pricing |
| API and manufacturing efficiency |
Main determinant of gross margin |
| Regulatory compliance |
Critical to preserving supply continuity |
How does Cardizem compare with competing calcium-channel blockers?
Cardizem competes clinically with other antihypertensive and antianginal drugs, but its commercial competition is broader than other branded calcium-channel blockers.
| Drug class |
Example |
Commercial comparison with Cardizem |
| Nondihydropyridine calcium-channel blocker |
Verapamil |
Similar rate-control role; also generic |
| Dihydropyridine calcium-channel blocker |
Amlodipine |
Larger hypertension market and broad generic use |
| Beta blocker |
Metoprolol |
Stronger competition in rate control and cardiovascular indications |
| Digoxin |
Digoxin |
Narrower clinical role and different safety profile |
| Antiarrhythmic agents |
Amiodarone |
Used in different treatment settings; higher safety and monitoring considerations |
Amlodipine and metoprolol generally have broader prescription exposure in hypertension and cardiovascular care. Diltiazem retains clinical relevance in rate control and selected angina settings, but this does not translate into branded pricing power.
What licensing deals affected Cardizem?
Cardizem’s historical commercial structure involved licensing, rights transfers, and successor-company ownership associated with Hoechst Marion Roussel, Aventis, Sanofi, and other pharmaceutical entities. Certain extended-release commercialization rights were also associated with Biovail during the period when controlled-release cardiovascular products were commercially important.
Those historical transactions no longer define the economics of the mature U.S. diltiazem market. Current value depends on approved generic rights, manufacturing capacity, and supply contracts rather than on an exclusive Cardizem licensing platform.
What is the regulatory outlook for diltiazem?
The FDA regulatory outlook is stable. Diltiazem remains an established small-molecule drug with multiple approved dosage forms. The main regulatory issues are product quality, bioequivalence, labeling compliance, manufacturing controls, and shortage management.
For generic manufacturers, the most important technical barriers are:
- Demonstrating bioequivalence for modified-release products.
- Matching dissolution profiles across multiple conditions.
- Controlling dose uniformity.
- Maintaining stability through the labeled shelf life.
- Managing drug-drug interaction information.
- Complying with current good manufacturing practice requirements.
These barriers can delay or increase the cost of generic development, but they do not support a branded monopoly.
What generic launch scenarios are plausible?
Three scenarios define the current market.
Base case: stable mature generic market
Multiple oral suppliers remain active, prices stay low, and no supplier controls the market. Cardizem brand sales remain commercially immaterial.
Upside case for a generic supplier: temporary supply concentration
A manufacturer gains share after a competitor exits, receives approval for a constrained strength, or benefits from a shortage. Revenue and pricing improve temporarily.
Downside case: accelerated price erosion
Additional ANDA approvals enter a high-volume strength, wholesalers consolidate purchasing, and suppliers compete primarily on price. Margins compress even if total prescription volume remains stable.
The most attractive opportunities are likely to involve constrained formulations, hospital injectable supply, or operationally difficult strengths rather than standard immediate-release tablets.
Key Takeaways
- Cardizem is a mature diltiazem brand with no meaningful current U.S. exclusivity advantage.
- Historical Cardizem CD patent litigation shaped generic-entry law but does not materially restrict today’s market.
- U.S. diltiazem revenue is now concentrated in generic oral products and hospital injectable supply.
- Cardizem-specific revenue is not separately disclosed by major public companies.
- The main commercial barriers are formulation execution, manufacturing quality, API supply, and distribution contracts.
- Biosimilar risk is irrelevant because diltiazem is a small molecule.
- Generic-entry risk is already realized; future financial changes will come from price erosion, supplier exits, shortages, and formulation-specific competition.
- The strongest residual commercial assets are manufacturing capability and reliable supply, not the Cardizem trademark or historical patent estate.
FAQs About Cardizem Market and Patent Status
Is Cardizem still sold as a branded drug?
Cardizem-branded products have limited commercial relevance in the United States. Generic diltiazem is the dominant source of supply.
Does Cardizem have an active composition-of-matter patent?
No commercially meaningful composition-of-matter exclusivity remains for diltiazem. The original protection expired long ago.
Can a generic manufacturer launch diltiazem without a Paragraph IV challenge?
For expired patents, a generic applicant does not need to create a current Paragraph IV dispute. The relevant FDA pathway is generally an ANDA referencing the applicable listed drug.
Is Cardizem CD interchangeable with Cardizem LA?
No. Extended-release diltiazem products use different formulations and release technologies. Interchangeability depends on the specific FDA therapeutic-equivalence designation and product strength.
Why can injectable diltiazem have better pricing than oral tablets?
Hospital injectable markets can have fewer approved suppliers, more demanding manufacturing requirements, and greater sensitivity to shortages. Those factors can support temporary pricing differences even when oral diltiazem is highly commoditized.
References
- U.S. Food and Drug Administration. (2023). Cardizem CD (diltiazem hydrochloride) extended-release capsules: Prescribing information.
- U.S. Food and Drug Administration. (2023). Cardizem LA (diltiazem hydrochloride) extended-release tablets: Prescribing information.
- U.S. Food and Drug Administration. (2023). Diltiazem hydrochloride injection: Prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Supreme Court of the United States. (2013). Federal Trade Commission v. Actavis, Inc., 570 U.S. 136.
